ImProDia

Company Overview

Snapshot

Founded in January 2012 by Tuvia Sofinzon and Raphael Nir, ImProDia operates with 1–10 employees. The company has raised $200K across two funding rounds, with Citrine S A L participating. In October 2014, ImProDia secured a funding round from Citrine S A L.

Business overview

ImProDia is a diagnostic company developing proprietary biomarker clusters to monitor the immunity status of patients with chronic inflammatory diseases. Its technology tracks disease regression, recurrence, and treatment response, aiming to identify patients most likely to benefit from specific therapeutic treatments and predict complications. The company's R&D focuses on creating a clinical prototype for multi-center trials, emphasizing product establishment, process standardization, and quality control validation. ImProDia operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Test Diagnostics & Screening, serving the healthcare and life sciences industries, including biotechnology, pharmaceuticals, and laboratories.

Company Intelligence Q&A

What is ImProDia's core technology?

ImProDia develops clusters of novel proprietary biomarkers designed for monitoring the immunity status of patients suffering from diseases associated with chronic inflammation.

When was ImProDia founded and by whom?

ImProDia was founded in January 2012 by Tuvia Sofinzon and Raphael Nir.

Which markets does ImProDia target?

ImProDia targets geomarkets in Europe and India with its diagnostic technologies.

What is the primary application of ImProDia's technology?

The technology enables the tracking of disease regression, recurrence, and treatment response, as well as immunity status, to help identify patients who will benefit most from particular therapeutic treatments.